SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports

被引:0
作者
Hibathulla Palapra
Subeesh K. Viswam
Vivekanandan Kalaiselvan
Krishna Undela
机构
[1] National Institute of Pharmaceutical Education and Research (NIPER) Guwahati,Department of Pharmacy Practice
[2] Manipal College of Pharmaceutical Sciences,Department of Pharmacy Practice
[3] Manipal Academy of Higher Education,undefined
[4] Indian Pharmacopoeia Commission,undefined
[5] Uttar Pradesh,undefined
来源
International Journal of Clinical Pharmacy | 2022年 / 44卷
关键词
Case reports; Detection; Disproportionality analysis; Pancreatitis; Pharmacovigilance; Signal; Sodium-glucose cotransporter-2 inhibitors;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1425 / 1433
页数:8
相关论文
共 64 条
[1]  
Tabish SA(2007)Is diabetes becoming the biggest epidemic of the twenty-first century? Int J Health Sci (Qassim) 1 V-VIII
[2]  
Saeedi P(2019)Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas Diabetes Res Clin Pract 157 107843-149
[3]  
Petersohn I(2014)Global estimates of diabetes prevalence for 2013 and projections for 2035 Diabetes Res Clin Pract 103 137-134
[4]  
Salpea P(2005)Diabetes mellitus and its treatment Int J Diabetes Metab 13 111-502
[5]  
Guariguata L(2012)SGLT-2 inhibition in diabetes mellitus: rationale and clinical prospects Nat Rev Endocrinol 8 495-311
[6]  
Whiting DR(2019)An update on the safety of SGLT-2 inhibitors Expert Opin Drug Saf 18 295-49
[7]  
Hambleton I(2018)Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review Rev Cardiovasc Med 19 41-1251
[8]  
Bastaki A(2017)SGLT-2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review Diabetes Ther 8 1245-803
[9]  
Ferrannini E(2013)Data mining of the public version of the FDA adverse event reporting system Int J Med Sci 10 796-63
[10]  
Solini A(2016)OpenVigil FDA–inspection of US American adverse drug events pharmacovigilance data and novel clinical applications PLoS ONE 11 e0157753-994